BioTime Announces the Appointment of Jeffrey Janus as Vice President

  BioTime Announces the Appointment of Jeffrey Janus as Vice President

 Adds senior executive with significant experience in sales and marketing of
                              research products

Business Wire

ALAMEDA, Calif. -- December 20, 2012

BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus
as its Vice President of Sales and Marketing. Mr. Janus’ primary focus will be
to create, market, and sell research products for BioTime and its subsidiaries
in the expanding field of regenerative medicine. Mr. Janus has more than 25
years of experience and a proven track record of creating profitable
commercial cell-based business.

“Jeffrey brings tremendous expertise in regenerative medicine, developing and
selling research products and reagents, and building business units,” said
Michael D. West, PhD, BioTime’s Chief Executive Officer. “We welcome Jeffrey
to the BioTime team and look forward to working together with him in expanding
our development, marketing, and sale of research products.”

“I am honored and excited to be a part of the BioTime team. It is especially
gratifying to be working with BioTime’s partner LifeMap Sciences, Inc. and
their unique and powerful on-line integrated database suite for genomic,
biomedical and stem cell research. This in-depth database suite, linked to
BioTime’s unique PureStem™ lines of standardized human progenitor cells, gives
researchers a comprehensive set of tools to study human embryonic development
and stem cell biology. Medical research has always depended upon the
availability of standardized research products and information, and BioTime
and LifeMap have become leaders in consolidating biomedical information with
standardized stem cells.”

Mr. Janus was most recently Senior Vice President of Operations at
International Stem Cell Corporation (OTCQB: ISCO), where he led the company to
discover a process known as parthenogenesis resulting in functional human
pluripotent stem cells without the use of fertilized human embryos, and was
previously the CEO and founder of Lifeline Cell Technology, LLC, a subsidiary
of ISCO. Prior to that, he was a member of the founding team that created
Clonetics Corporation and the Clonetics brand of primary human cell products.
In addition to his extensive experience in developing and selling cell-based
products to the research market, Mr. Janus has led teams of scientists both
internally and through external domestic and international collaborations with
major academic institutions to conduct research. He has grown several
biotechnology companies from the ground up, from licensing or patenting
intellectual property, to building teams to develop, manufacture and market
products profitably. He has a deep understanding of the process of creating
and managing teams and has used the strategic planning process to great
success.

Mr. Janus has a Masters Degree in Business Administration from California
State University, San Diego and a Bachelor Degree in Biochemistry from the
University of California at Davis and is a published author of breakthrough
papers in the field of parthenogenesis and stem cell research.

About BioTime, Inc.

BioTime, headquartered in Alameda, Calif., is a biotechnology company focused
on regenerative medicine and blood plasma volume expanders. Its broad platform
of stem cell technologies is enhanced through subsidiaries focused on specific
fields of application. BioTime develops and markets research products in the
fields of stem cells and regenerative medicine, including a wide array of
proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc., markets GeneCards^®, the leading human gene database, and has developed
an integrated database suite to complement GeneCards^® that includes the
LifeMap Discovery™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap is
also marketing BioTime research products. BioTime's lead product, Hextend^®,
is a blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc., and in South Korea by CJ CheilJedang Corporation under
exclusive licensing agreements. Additional information about BioTime can be
found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390, ext 367
pgarcia@biotimemail.com
or
Judith Segall
510-521-3390, ext 301
jsegall@biotimemail.com
 
Press spacebar to pause and continue. Press esc to stop.